My name is Tim Bateman. I'm here with Dr. Gary Hiller and Dr. Panethia Sharon Thedaoui, and we're going to be discussing your presentation when you reviewed the Phase III studies on F18 flirperidase. You spoke quite a bit about the results in bigger patients, you know, in obese people. Do you want to tell us a little bit about what we learned from that study? Yeah. Thanks, Tim. Thanks for having me. And so flirperidase PET in the group of patients with BMI at least 30 had higher or better image quality as compared to conventional SPECT myocardial perfusion imaging. Also had higher interpretive certainty, meaning that physicians interpreting the images were more certain about what they were seeing, and also had higher diagnostic accuracy, again, as compared to conventional SPECT myocardial perfusion imaging. Yeah. I was particularly intrigued by this finding that the sensitivity and specificity in obese patients was the same as it was in non-obese patients. I don't think we've had any studies in the past with any other tracers that have managed to show that. Yeah. You're absolutely right, Tim. I think that patients with larger body habitus are really quite a challenge for us. And most of the time, we were dealing with a lot of artifacts and lower specificity. And so it was surprising, but I think really excellent data. So what do you think it is about a fluorinated PET tracer that permits that, that we can image big people and get excellent images, and as high a diagnostic accuracy as in smaller people? Yeah. So I think higher energy as compared to SPECT imaging. And fluorperidase also has a higher extraction fraction. And some of these with higher contrast resolution as well. So I think some of these properties help to improve image quality. So I'm interested in your perspectives. You're one of the leaders in nuclear cardiology. So what impact do you think an F18 agent, such as fluorperidase, will have on the field in general? Yeah. So I think aside from the better image quality and high diagnostic accuracy, which I think is really beneficial to patients, is the unit dose ability to be able to acquire the dosing without an on-site cyclotron, or having, say, a contract and having a rubidium generator that's going to be in the scanner room on site. So there's a little bit more flexibility of maybe adding it to maybe an existing practice, or even starting anew, or even trying it out. For example, if there are PET scanners already readily available with time slots, but they're mainly used for oncology, you might be able to try a unit dose of fluorperidase and try it out in a single patient, or maybe do it a couple times a week just to start. So you think this might have the potential to expand the PET community, which is very exciting for all of us. Yes, absolutely. I mean, to kind of democratize PET and make it more available to more patients. And we know that PET offers superior technology than what a lot of places are currently using with SPECT MPI. So I think that this definitely could really benefit our patients and improve patient care and the management of our patients with suspected or known CAD and microvascular dysfunction. So a lot of great potential for its use. It kind of seems like PET has been confined to larger practices and larger hospitals. So this might really open things up. Yeah, I think there's a lot of potential, depending on pricing and just convenience. But I think there's a lot of potential for many places to try out cardiac PET, even places where before they just had too many barriers, too many obstacles. That's terrific news for patient care. Yes, I agree, Gary. So most of our PET cameras are designed to image F18 agents, right? And this study was carried out, I believe, without very many high-end PET scanners, but kind of covered the array of legacy cameras and so forth. And image quality still turned out to be high quality. Any thoughts about that? Yeah. I mean, we saw in the 303 trial, in the latest phase 3 part 2 trial, that there was very high readers rate at the image quality is very high, up in the 90% or more for either excellent or good image quality. So I think this is really excellent, and we're going to be able to help many of our different patients. This was true in all comers, in the entire population in the study, but also in the larger populations, as we mentioned, in women. And women have certain, they're a special population in terms of chest pain and chest pain syndromes, as well as microvascular dysfunction. So there's a lot of potential applications there, and also in diabetic patients. So a lot of potential applications and strengths. Well, thank you for your insights on those studies, and I think we've learned a lot from your discussions. And it will be interesting to see all the new research that's going to come out with this new tracer over the next several years. Thank you for having me. Thank you.

F18 flirperidase

Phase III studies

obese patients

PET imaging

nuclear cardiology